Skip to main content
SpringerLink
Log in

Introduction

  • Chapter
  • First Online:
Regulation of Cancer Immune Checkpoints

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1248))

Abstract

Cancer immunotherapy, especially immune checkpoint blockade therapy, represents a hotspot in cancer research. However, the low response rate, adaptive/acquired resistance, and adverse effects still keep most cancer patients from obtaining sustained clinical benefits. To overcome these limitations, it is essential to improve our understanding on the regulation of immune checkpoints under physiological and pathological contexts. Recent researches have gained insights into the molecular control of immune checkpoint receptors and ligands, which extended our knowledge on the immune system and provided alternative strategies for developing checkpoint inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Allison JP (2015) Immune checkpoint blockade in cancer therapy: the 2015 Lasker-DeBakey clinical medical research award. JAMA 314(11):1113–1114. PubMed PMID: 26348357

    Google Scholar 

  • Brahmer JR (2013) Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 31(8):1021–1028. PubMed PMID: 23401435

    Google Scholar 

  • Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195–207. PubMed PMID: 28106152. Pubmed Central PMCID: 5629093

    Google Scholar 

  • Hafner A, Bulyk ML, Jambhekar A, Lahav G (2019) The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol 20(4):199–210. PubMed PMID: 30824861

    Google Scholar 

  • Hassounah NB, Malladi VS, Huang Y, Freeman SS, Beauchamp EM, Koyama S et al (2019) Identification and characterization of an alternative cancer-derived PD-L1 splice variant. Cancer Immunol Immunother: CII 68(3):407–420. PubMed PMID: 30564890. Pubmed Central PMCID: 6428600

    Google Scholar 

  • Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E et al (2015) Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162(6):1242–1256. PubMed PMID: 26359984. Pubmed Central PMCID: 4700833

    Google Scholar 

  • Li H, Li X, Liu S, Guo L, Zhang B, Zhang J et al (2017) Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology 66(6):1920–1933. PubMed PMID: 28732118

    Google Scholar 

  • Liang L, Wang H, Shi H, Li Z, Yao H, Bu Z et al (2018) A designed peptide targets two types of modifications of p 53 with anti-cancer activity. Cell Chem Biol 25(6):761–774 e5. PubMed PMID: 29681526

    Google Scholar 

  • Minton K (2014) T cell signalling: p53 controls the crowd. Nat Rev Immunol 14(6):358. PubMed PMID: 24810199

    Google Scholar 

  • Nishino M, Ramaiya NH, Hatabu H, Hodi FS (2017) Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol 14(11):655–668. PubMed PMID: 28653677. Pubmed Central PMCID: 5650537

    Google Scholar 

  • Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM (2018) Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol 15(4):222–234. PubMed PMID: 29512649

    Google Scholar 

  • Sury K, Perazella MA, Shirali AC (2018) Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol 14(9):571–588. PubMed PMID: 30013100

    Google Scholar 

  • Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y (2018) Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov 17(12):854–855. PubMed PMID: 30482962

    Google Scholar 

  • Villanueva MT (2017) Cancer immunotherapy: searching in the immune checkpoint black box. Nat Rev Drug Discov 16(9):599. PubMed PMID: 28799544

    Google Scholar 

  • Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J (2018) Regulation of PD-L1: emerging routes for targeting tumor immune evasion. Front Pharmacol 9:536. PubMed PMID: 29910728. Pubmed Central PMCID: 5992436

    Google Scholar 

  • Webster RM (2014) The immune checkpoint inhibitors: where are we now? Nat Rev Drug Discov 13(12):883–884. PubMed PMID: 25345674

    Google Scholar 

  • Wykes MN, Lewin SR (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18(2):91–104. PubMed PMID: 28990586. Pubmed Central PMCID: 5991909

    Google Scholar 

  • Yao H, Wang H, Li C, Fang JY, Xu J (2018) Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy. Front Immunol 9:1774. PubMed PMID: 30105035. Pubmed Central PMCID: 6077319

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, 200040, China

    Jie Liu

  2. Department of Immunology, State Key Laboratory of Genetic Engineering, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200433, China

    Jie Liu

  3. Institutes of Biomedical Sciences, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, 200032, China

    Jie Xu

Authors
  1. Jie Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jie Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jie Xu .

Editor information

Editors and Affiliations

  1. Institutes of Biomedical Sciences, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

    Jie Xu

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Liu, J., Xu, J. (2020). Introduction. In: Xu, J. (eds) Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, vol 1248. Springer, Singapore. https://doi.org/10.1007/978-981-15-3266-5_1

Download citation

Publish with us

Policies and ethics

Search

Navigation